We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Proteomics Technique for Lung Cancer Prognosis

By Biotechdaily staff writers
Posted on 19 Aug 2003
Cancer researchers have used a proteomics-based approach to develop a method for predicting the likely clinical outcome of lung cancer by using a minute sample of lung cancer tissue.

Investigators at Vanderbilt University (Nashville, TN, USA) used mass spectrometry and customized software to analyze samples from 79 lung tumors and tissue from 14 normal lungs. More...
The samples were only one millimeter in diameter and one nanometer in thickness.

Applying a customized computer program, they were able to distinguish lung tumor from normal lung; primary nonsmall cell lung cancer (NSCLC) from normal lung; primary NSCLC from cancer that had spread to the lungs from other organs; and adenocarcinomas from squamous cell carcinomas and squamous cell carcinomas from large cell carcinomas. Most importantly, they were able to predict the risk that the cancer would spread to nearby lymph nodes.

"Involvement of lymph nodes is one of the most important factors in determining treatment strategies, so the clinical implications of these data could be significant,” explained senior author Dr. David P. Carbone, professor of medicine and cancer biology at Vanderbilt University. "Being able to use molecular markers to divide patients into high- or low-risk groups would also be very useful in determining treatment strategy.”




Related Links:
Vanderbilt University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.